DDInter1834 DDInter1180
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Topiramate {u} (Compound) treats {v} (Disease) obesity
Topiramate {u} (Compound) binds {v} (Gene) GABRB2
Topiramate {u} (Compound) upregulates {v} (Gene) UBQLN2
Topiramate {u} (Compound) palliates {v} (Disease) bipolar disorder
Topiramate {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Topiramate {u} (Compound) downregulates {v} (Gene) CDC20
Topiramate {u} (Compound) causes {v} (Side Effect) Hyperchloraemia
Topiramate (Compound) treats obesity (Disease)
Topiramate (Compound) binds GABRB2 (Gene)
Topiramate (Compound) upregulates UBQLN2 (Gene)
Topiramate (Compound) palliates bipolar disorder (Disease)
Topiramate (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Topiramate (Compound) downregulates CDC20 (Gene)
Topiramate (Compound) causes Hyperchloraemia (Side Effect)